Faculty Profiles - NAKAMURA Kazufumi

MISC - NAKAMURA Kazufumi

Division display 61 - 80 of about 472 ／ All the affair displays >>

ペースメーカリード抜去術後に発症した,たこつぼ心筋症の1例

寺西仁, 西井伸洋, 宮本真和, 森本芳正, 川田哲史, 更科俊洋, 高谷陽一, 杜徳尚, 中川晃志, 赤木達, 吉田賢司, 谷山真規子, 渡邊敦之, 三好亨, 赤木禎治, 中村一文, 森田宏, 伊藤浩

日本循環器学会中国地方会(Web) 111th 2017

MRIで示唆された心筋障害部位への通電により房室副伝導路の離断,および持続性心室頻拍,心室性期外収縮を根治しえた1例

森本芳正, 中川晃志, 渡邊敦之, 川田哲史, 橘元見, 西井伸洋, 中村一文, 森田宏, 伊藤浩

心臓 49 2017

大動脈側周囲縁欠損心房中隔欠損症に対するカテーテル治療:Occlutech Figulla Flex IIの有用性

中川晃志, 赤木禎治, 高谷陽一, 中村一文, 森田宏, 伊藤浩

日本Pediatric Interventional Cardiology学会学術集会プログラム抄録集 28th 2017

His束近傍起源ATP感受性心房頻拍をentrainment pacingを指標に根治しえた1例

森本芳正, 中川晃志, 渡邊敦之, 川田哲史, 橘元見, 西井伸洋, 中村一文, 森田宏, 伊藤浩

日本循環器学会中国地方会(Web) 110th 2017

Coronary Plaque Erosionが原因と考えられたAMIの1例

戸田洋伸, 網岡尚史, 吉田雅言, 中川晃志, 渡邉敦之, 三好亨, 西井伸洋, 中村一文, 森田宏, 伊藤浩

日本循環器学会中国地方会(Web) 110th 2017

運動負荷試験中にwide QRS tachycardiaを来したBrugada症候群の1例

宮本真和, 森田宏, 森本芳正, 三好章仁, 川田哲史, 寺西仁, 中川晃志, 西井伸洋, 渡邊敦之, 中村一文, 伊藤浩

日本循環器学会中国地方会(Web) 111th 2017

Late R’ Wave Axis of Complete Right Bundle Branch Block Represents Conduction Disturbance within Right Ventricle in Brugada Syndrome

森本芳正, 森田宏, 川田哲史, 橘元見, 中川晃志, 渡辺敦之, 西井伸洋, 中村一文, 伊藤浩

日本循環器学会学術集会(Web) 81st 2017

Measurement of epicardial fat thickness by transthoracic echocardiography for predicting high-risk coronary artery plaques

Motomi Tachibana, Toru Miyoshi, Kazuhiro Osawa, Norihisa Toh, Hiroki Oe, Kazufumi Nakamura, Takanori Naito, Shuhei Sato, Susumu Kanazawa, Hiroshi Ito

HEART AND VESSELS 31 ( 11 ) 1758 - 1766 2016.11

Language：English Publisher：SPRINGER

Epicardial adipose tissue (EAT) volume is reported to be associated with coronary plaques. We evaluated whether non-invasive measurement of EAT thickness by echocardiography can predict high-risk coronary plaque characteristics determined independently by coronary computed tomography (CT) angiography. We enrolled 406 patients (mean age 63 years, 57 % male) referred for 64-slice CT. EAT was measured on the right ventricle free wall from a parasternal long-axis view at the end of systole. High-risk coronary plaques were defined as low-density plaques (< 30 Hounsfield units) with positive remodeling (remodeling index > 1.05). Patients were divided into thin or thick EAT groups using a cutoff value derived from receiver operator characteristic curve analysis for discriminating high-risk plaques. The receiver operator characteristic cutoff value was 5.8 mm with a sensitivity of 83 % and specificity of 64 % (area under the curve 0.77, 95 % confidence interval 0.70-0.83, p < 0.01). Compared with the thin EAT group, the thick EAT group had a high prevalence of low-density plaques (4 vs. 24 %, p < 0.01), positive remodeling (39 vs. 60 %, p < 0.01), and high-risk plaques (3 vs. 17 %, p < 0.01). Multiple logistic analysis revealed that thick EAT was a significant predictor of high-risk plaques (odds ratio 7.98, 95 % confidence interval 2.77-22.98, p < 0.01) after adjustment for covariates, including conventional risk factors, visceral adipose tissue area, and medications. The measurement of EAT thickness by echocardiography may provide a non-invasive option for predicting high-risk coronary plaques.

DOI： 10.1007/s00380-016-0802-5

Web of Science

researchmap

Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension

Satoshi Akagi, Kazufumi Nakamura, Hiromi Matsubara, Megumi Kondo, Daiji Miura, Tetsuya Matoba, Kensuke Egashira, Hiroshi Ito

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 67 ( 4 ) 290 - 298 2016.4

Language：English Publisher：LIPPINCOTT WILLIAMS & WILKINS

Nanoparticles (NPs) have been used as novel drug delivery systems. Drug-incorporated NPs for local delivery might optimize the efficacy and minimize the side effects of drugs. Intravenous prostacyclin improves long-term survival in patients with pulmonary arterial hypertension (PAH), but it causes serious side effects such as catheter-related infections. We investigated the efficacy and safety of intratracheal administration of a prostacyclin analogue, beraprost (BPS), incorporated NPs in Sugen-hypoxia-normoxia and monocrotaline rat models of PAH and in human PAH pulmonary arterial smooth muscle cells (PASMCs). After a single administration, BPS NPs significantly decreased right ventricular pressure, right ventricular hypertrophy, and pulmonary artery muscularization in the 2 rat models. BPS NPs significantly improved the survival rate in the monocrotaline rat model. No infiltration of inflammatory cells, hemorrhage, or fibrosis was found in the liver, kidney, spleen, and heart after the administration of BPS NPs. No liver or kidney dysfunction was found in the blood examinations. BPS and BPS NPs significantly inhibited the proliferation of human PAH PASMCs after 24 hours of treatment. BPS NPs significantly continued to inhibit the proliferation of human PAH PASMCs at 24 hours after the removal of BPS NPs. BPS NPs significantly induced apoptosis in PAH PASMCs compared to that in non-PAH PASMCs. Intratracheal administration of BPS NPs ameliorates pulmonary hypertension in PAH rat models by a sustained antiproliferative effect and a proapoptotic effect on PAH PASMCs.

DOI： 10.1097/FJC.0000000000000352

Web of Science

researchmap

Association between coronary artery calcification and left ventricular diastolic dysfunction in elderly people

Kazuhiro Osawa, Toru Miyoshi, Hiroki Oe, Shuhei Sato, Kazufumi Nakamura, Kunihisa Kohno, Hiroshi Morita, Susumu Kanazawa, Hiroshi Ito

HEART AND VESSELS 31 ( 4 ) 499 - 507 2016.4

Language：English Publisher：SPRINGER

Coronary artery calcification (CAC) is associated with the incidence of congestive heart failure. We evaluated the association between CAC and left ventricular diastolic dysfunction (LVDD) in elderly patients without coronary artery disease. Coronary computed tomography was performed in 1,021 consecutive patients > 55 years of age who were suspected of having coronary artery disease. A total of 530 patients (age, 70 +/- A 8 years; 56 % men) with a LV ejection fraction > 50 % and without obstructive coronary artery disease and a history of coronary artery disease were included in the analysis. LVDD was defined according to a standard algorithm by echocardiography (septal e' < 8, lateral e' < 10, and left atrial volume index a parts per thousand yen34 mL/m(2)). A total of 224 of 530 patients had LVDD. CAC scores in patients with LVDD were higher than those in patients without LVDD (p < 0.01). The prevalence of LVDD in patients with CAC scores a parts per thousand yen400 was greater than that in patients with CAC scores of 0-9 (58 vs. 34 %, p < 0.01). After adjustment for confounding factors, the CAC score was associated with LVDD, with an odds ratio of 1.96 (95 % confidence interval: 1.11-3.43, p = 0.02) for a CAC score a parts per thousand yen400 compared with a CAC score of 0-9. A CAC score a parts per thousand yen400 was associated with LVDD in elderly patients without CAD in this population. Further prospective studies are needed to evaluate the clinical relevance of CAC as a risk of heart failure with preserved ejection fraction.

DOI： 10.1007/s00380-015-0645-5

Web of Science

researchmap

Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension

Nobutoshi Nawa, Hidekazu Ishida, Shinichi Katsuragi, Hiroki Baden, Kunihiko Takahashi, Ryota Higeno, Fumiko Torigoe, Seiko Mihara, Jun Narita, Kohji Miura, Kazufumi Nakamura, Shigetoyo Kogaki, Keiichi Ozono

Molecular Therapy - Methods and Clinical Development 3 16044 - 16044 2016.3

Language：English Publisher：Elsevier Inc

We recently found a constitutively active mutant of natriuretic peptide receptor 2 (caNPR2
V883M), which synthesizes larger amounts of cyclic guanosine monophosphate (cGMP) intracellularly without any ligand stimulation than existing drugs. The aim of this study was to investigate the therapeutic effects of gene transduction using caNPR2 for pulmonary arterial hypertension (PAH). In vitro gene transduction into human pulmonary arterial smooth muscle cells using Sendai virus (SeV) vectors carrying caNPR2 induced 10,000-fold increases in the synthesis of cGMP without ligand stimulation, and the proliferation of caNPR2-expressing cells was significantly attenuated. The PAH model rats generated by hypoxia and the administration of SU5416 were then treated with SeV vectors through a direct injection into the left pulmonary artery. Right ventricular systolic pressure was significantly decreased 2 weeks after the treatment, while systemic blood pressure remained unchanged. Histological analyses revealed that the medial wall thickness and occlusion rate of pulmonary arterioles were significantly improved in caNPR2-treated lungs. Neither the systemic integration of virus vectors nor side effects were observed. The massive stimulation of cGMP synthesis by gene therapy with caNPR2 was safe and effective in a PAH rat model and, thus, has potential as a novel therapy for patients with severe progressive PAH.

DOI： 10.1038/mtm.2016.44

Scopus

researchmap

Postprandial hyperlipidemia as a potential residual risk factor

Kazufumi Nakamura, Toru Miyoshi, Kei Yunoki, Hiroshi Ito

JOURNAL OF CARDIOLOGY 67 ( 3-4 ) 335 - 339 2016.3

Language：English Publishing type：Book review, literature introduction, etc. Publisher：ELSEVIER SCIENCE BV

Statin therapy targeting reduction of low-density lipoprotein cholesterol (LDL-C) decreases the risk of coronary heart disease (CHD) and all-cause mortality. However, a substantial number of cases of CHD are not prevented and residual risk factors remain unsettled. A high triglyceride (TG) level is considered to be an important and residual risk factor. Postprandial hyperlipidemia is a condition in which TG-rich chylomicron remnants are increased during the postprandial period and hypertriglycedemia is protracted. Postprandial hyperlipidemia evokes atherogenesis during the postprandial period. Several prospective studies have revealed that nonfasting serum TG levels predict the incidence of CHD. Values of TG, remnant lipoprotein cholesterol, and remnant lipoprotein TG after fat loading were significantly higher in diabetes patients with insulin resistance than in diabetes patients without insulin resistance.
Endothelial dysfunction is an initial process of atherogenesis and it contributes to the pathogenesis of CHD. Postprandial hyperlipidemia (postprandial hypertriglyceridemia) is involved in the production of proinflammatory cytokines, recruitment of neutrophils, and generation of oxidative stress, resulting in endothelial dysfunction in healthy subjects, hypertriglyceridemic patients, or type 2 diabetic patients.
Effective treatment has not been established till date. Ezetimibe or omega-3 fatty acids significantly decrease postprandial TG elevation and postprandial endothelial dysfunction. Ezetimibe or omega-3 fatty acids added to statin therapy reduce serum TG levels and result in good outcomes in patients with CHD.
In conclusion, postprandial hyperlipidemia is an important and residual risk factor especially in patients with insulin resistance syndrome (metabolic syndrome) and diabetes mellitus. Further studies are needed to establish effective treatment. (C) 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

DOI： 10.1016/j.jjcc.2015.12.001

Web of Science

researchmap

Celsior preserves cardiac mechano-energetics better than University of Wisconsin solution by preventing oxidative stress

Takahiko Kiyooka, Yu Oshima, Waso Fujinaka, Gentaro Iribe, Juichiro Shimizu, Satoshi Mohri, Kazufumi Nakamura

INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY 22 ( 2 ) 168 - 175 2016.2

Language：English Publisher：OXFORD UNIV PRESS

OBJECTIVES: Identity of the optimal heart preservation solution remains unknown. Because oxidative stress contributes to contractile failure in the ischaemic/reperfused myocardium and the main characteristic of Celsior is its antioxidant effect, it is important to elucidate the relationship between the inhibitory effect on oxidative stress and cardiac mechano-energetics. We therefore evaluated the efficacy of Celsior from both aspects by comparison with the University of Wisconsin solution (UWS).
METHODS: We used 18 excised cross-circulated canine hearts. Excised hearts were preserved with UWS (n = 6) or Celsior (n = 6) for 3 h at 4 degrees C; the remaining six served as controls. Hearts were then cross-circulated and rewarmed. The end-systolic pressure-volume ratio (LV E-max) and the ventricular pressure-volume area, which is a measure of total mechanical energy, were assessed after reperfusion. Biopsies were taken from the endocardium after excising the heart, before reperfusion, after reperfusion and 4 h after reperfusion to assess the inhibitory effect of each agent on oxidative stress. Endo-myocardial biopsy samples were studied immunohistochemically for expression of 4-hydroxy-2-nonenal (HNE)-modified protein, which is a major lipid peroxidation product.
RESULTS: E-max in the UWS group was significantly smaller than in the control group, whereas the E-max in the Celsior group was preserved. Oxygen cost of E-max in the UWS group was significantly higher than in the Celsior group. Myocardial HNE-modified protein levels increased gradually, both under preservation and after reperfusion in the UWS group. Myocardial HNE-modified protein levels in the Celsior group were lower, mainly before and 4 h after reperfusion compared with the UWS group.
CONCLUSIONS: Celsior may maintain cardiac contractility and conserve oxygen cost by inhibiting oxidative stress.

DOI： 10.1093/icvts/ivv324

Web of Science

researchmap

Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size

Hironobu Toda, Kazufumi Nakamura, Makoto Nakahama, Tadashi Wada, Atsuyuki Watanabe, Bkatsushi Hashimoto, Ritsuko Terasaka, Koji Tokioka, Nobuhiro Nishii, Toru Miyoshi, Kunihisa Kohno, Yusuke Kawai, Kohei Miyaji, Yuji Koide, Motomi Tachibana, Ryo Yoshioka, Hiroshi Ito

JOURNAL OF CARDIOLOGY 67 ( 1-2 ) 177 - 183 2016.1

Language：English Publisher：ELSEVIER SCIENCE BV

Background: Recent clinical trials have demonstrated the efficacy of short-term treatment with tolvaptan, an oral vasopressin V2 receptor antagonist, in patients with heart failure. However, the response to tolvaptan varies among patients. The aim of this study was to determine factors associated with response to tolvaptan in patients with acute decompensated heart failure (ADHF).
Methods: The Tolvaptan Registry, a prospective, observational, multicenter cohort study performed in Japan, aims to determine factors affecting the responsiveness of tolvaptan in patients with ADHF. We enrolled ADHF patients treated with tolvaptan and they were divided into two groups: responders and non-responders. Responders were defined as subjects who met all of the following three conditions: (1) increasing urine volume during a 24-hour period after the start of tolvaptan treatment; (2) improvement in New York Heart Association functional class; and (3) decrease in cardiothoracic ratio assessed by chest X-ray on day 3 of tolvaptan administration.
Results: Among the 114 patients, treatment with tolvaptan improved three conditions of heart failure in more than half of all the cohorts (71 patients, 62%). As for baseline characteristics, estimated glomerular filtration rate, urine osmolality, and kidney size were significantly greater in responders than in non responders. Multivariate logistic analysis revealed that kidney size was independently associated with responders (odds ratio: 1.083, p = 0.001, 95% confidence interval 1.031-1.137).
Conclusions: The main clinical characteristic of responders to treatment with tolvaptan is that kidney size is preserved. (C) 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

DOI： 10.1016/j.jjcc.2015.04.017

Web of Science

researchmap

Treatment for pulmonary hypertension due to left heart diseases

Kazufumi Nakamura

HYPERTENSION RESEARCH 39 ( 1 ) 6 - 7 2016.1

PCPS管理にて経過良好で後遺症なく独歩退院できた劇症型心筋炎の一例

大塚寛昭, 中村一文, 網岡尚史, 木村朋生, 中川晃志, 赤木達, 笠原真悟, 清水一好, 渡邊謙, 伊藤浩

日本循環器学会中国地方会(Web) 109th 2016

肺高血圧症の基礎研究から臨床研究への橋渡し（共著）

中村一文, 赤木達

呼吸と循環 64 ( 6 ) 582 - 587 2016

Translational research on pulmonary hypertension（共著）

Kazufumi Nakamura, Satoshi Akagi

Respiration and Circulation 64 ( 6 ) 582 - 587 2016

Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (repair and treat) in patients with pulmonary hypertension associated with atrial septal defect（共著）

Satoshi Akagi, Kazufumi Nakamura, Teiji Akagi, Koji Nakagawa, Yoichi Takaya, Toshihiro Sarashina, Kentaro Ejiri, Hiroshi Ito

Acta Medica Okayama, Acta. Medica Okayama, Acta medicinae Okayama, Acta medica Okayama 70 ( 5 ) 397 - 400 2016

初期スクリーニング・病態評価における心エコー検査の意義・現時点での限界・将来性（共著）

更科俊洋, 赤木達, 麻植浩樹, 中村一文, 伊藤浩

内科 117 ( 3 ) 383 - 390 2016

　 PREV - NEXT 　

< NAKAMURA Kazufumi >

MISC - NAKAMURA Kazufumi